EBV-Targeted Cell Vaccine Resolving Antigen Specificity

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current GM-CSF-secreting cellular vaccines for cancer are not specific to defined tumor antigens, making it difficult to evaluate fully their anti-tumor immune responses.

Innovation Solution

A human cell line lacking MHC-I and MHC-II antigens is modified to express a nucleotide sequence encoding an immunomodulator and a viral antigen, such as Epstein-Barr virus (EBV), to create a vaccine that induces a specific immune response against EBV-associated cancers.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If a universal GM-CSF-secreting cell line is used in combination with tumor cells, then the immunological activity and constant cytokine production are maintained, but the vaccine is not specific for a defined tumor antigen

Engineering Contradiction:

Improveimmunological activityVSAvoidantigen specificity

Core Design Contradiction:

ReliabilityVSManufacturing precision

Solution Approach 1:

The patent combines a universal GM-CSF-secreting cell line with a defined viral antigen (EBV) expressed on the same cell line. This merging allows the vaccine to maintain constant immunological activity from the GM-CSF while simultaneously providing specificity for a defined tumor antigen (EBV), resolving the contradiction between reliability and manufacturing precision

Inventive Principle:

Principle #5Merging (Combining)

Solution Approach 2:

The cell line is engineered to perform multiple functions: it secretes GM-CSF to provide universal immunological stimulation while also expressing a specific viral antigen to provide tumor-specific targeting. This multi-functionality allows a single vaccine composition to achieve both broad immunological activity and specific antigen recognition

Inventive Principle:

Principle #6Universality (Multi-functionality)

2Manufacturing precision

If autologous tumor cells are modified to express GM-CSF, then the vaccine is specific to the patient's tumor, but the process is highly individualized, expensive, and labor-intensive

Engineering Contradiction:

Improvetumor-specificityVSAvoidproduction complexity

Core Design Contradiction:

Manufacturing precisionVSEase of manufacture

Solution Approach 1:

Instead of modifying each patient's autologous tumor cells (which is complex and expensive), the patent uses a universal cell line that is once-and-for-all engineered to secrete GM-CSF and express the viral antigen. This copied approach maintains tumor-specificity through the viral antigen while dramatically simplifying manufacturing by eliminating the need for individualized cell modification

Inventive Principle:

Principle #26Copying

Solution Approach 2:

The patent changes the source of tumor-specificity from the tumor cell itself to a viral antigen expressed on a universal cell line. This parameter change allows the vaccine to maintain specificity while transitioning from a complex, individualized process to a simpler, standardized production process

Inventive Principle:

Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This approach allows for the evaluation of anti-tumor immune responses and potentially improves the targeting and efficacy of cancer vaccines by stimulating an immune response to defined viral antigens, such as EBV-associated cancers.

Implementation Method 1

GM-CSF induces the differentiation of primitive hematopoietic precursors into dendritic cells (DC), a type of antigen-presenting cell (APC) that initiates the most potent T-cell responses

Methodology Applied

Scientific EffectGM-CSF-induced differentiation:

Implementation Method 2

Methodology Applied

Scientific EffectViral antigen expression:

Data Source

PatentUS7740871B2Cancer immunotherapy with a viral antigen-defined, immunomodulator-secreting cell vaccine

Publication Date: 2010.06.22 JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE

AI summary

A human cell line, which lacks major histocompatibility class I (MHC-I) antigens and major histocompatibility class II (MHC-II) antigens and which has been modified to comprise and express (i) a nucleotide sequence encoding an immunomodulator and (ii) a nucleotide sequence encoding a viral antigen, and a method of inducing or stimulating an immune response in a human to a viral-associated disease or cancer comprising administering to the human (i) the aforementioned human cell line in an amount sufficient to induce or stimulate an immune response to the viral associated disease or cancer, (ii) a human cell line, which lacks MHC-I and MHC-11 antigens and which has been modified to comprise and express a nucleotide sequence encoding an immunomodulator, and a human cell line, which lacks MHC-I and MHC-II antigens and which has been modified to comprise and express a nucleotide sequence encoding an antigen of EBV, simultaneously or sequentially in either order, by the same or different routes, in amounts sufficient to induce or stimulate an immune response to the viral-associated disease or cancer, or (iii) an immunomodulator and a human cell line, which lacks MHC-I and MHC-II antigens and which has been modified to comprise and express a nucleotide sequence encoding an antigen of EBV, simultaneously or sequentially in either order, by the same or different routes, in amounts sufficient to induce or stimulate an immune response to the viral associated disease or cancer.